Immunotherapy duo aims to shrink nasopharyngeal tumors before standard treatment
NCT ID NCT07650266
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times
Summary
This trial tests whether adding the immunotherapy drugs cemiplimab (with or without fianlimab) to standard chemotherapy before chemoradiation can improve outcomes for people with advanced nasopharyngeal cancer. About 60 adults with non-metastatic, EBV-positive nasopharyngeal carcinoma will receive the drugs along with gemcitabine and cisplatin, followed by personalized chemoradiation. The main goal is to see how many patients have their tumors completely disappear after the initial treatment phase.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cemiplimab and fianlimab
- What this could lead to
- If successful, this approach could improve tumor shrinkage before standard treatment, potentially leading to better long-term control of nasopharyngeal cancer.
- What could go wrong
- This is an early-phase pilot study with only 60 participants, so results may not apply broadly. Adding immunotherapy to chemotherapy can increase side effects like immune-related inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen (Limited Protocol Activities )
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065, United States
-
Memorial Sloan Kettering Monmouth (Limited protocol activities)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Westchester (Limited protocol activities)
Harrison, New York, 10604, United States
-
Memorial Sloan Kettering at Nassau (Limited Protocol Activities)
Uniondale, New York, 11553, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could adding extra chemo before standard therapy beat nasopharyngeal cancer?
- Smart T-Cell engager aims to outsmart tumors in first human test
- Sharper radiation boost aims to tackle head and neck cancers that return
- Mouth rinse could ease painful radiation side effects for head and neck cancer patients
- Immunotherapy combo shows promise in shrinking Hard-to-Treat head and neck tumors
- New radiation approach aims to reduce dry mouth in throat cancer patients